StockNews.com began coverage on shares of OncoCyte (NYSE:OCX – Get Rating) in a report published on Wednesday morning. The brokerage issued a sell rating on the stock.
OncoCyte Price Performance
Shares of OCX stock opened at $0.39 on Wednesday. The company’s 50-day moving average price is $0.41. OncoCyte has a 12 month low of $0.24 and a 12 month high of $1.75. The firm has a market capitalization of $46.27 million, a price-to-earnings ratio of -0.60 and a beta of 1.73.
OncoCyte (NYSE:OCX – Get Rating) last announced its quarterly earnings results on Thursday, November 10th. The company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.05. The firm had revenue of $1.02 million for the quarter, compared to analyst estimates of $1.50 million.
OncoCyte Company Profile
OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. Its products include DetermaRx and DetermaIO. The firm also offers pharmaceutical services like multi-analyte test development and clinical trial services.
- Get a free copy of the StockNews.com research report on OncoCyte (OCX)
- Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
- Zimmer Biomet Beats on Earnings, Growth May be Priced In
- AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
- Ford Stock Going Forward After Big Earnings Flop
- Insiders And Institutions Buy Wolverine Worldwide
Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.